Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma

2018-05-22 18:49:10 | BioPortfolio

Published on BioPortfolio: 2018-05-22T18:49:10-0400

Clinical Trials [101 Associated Clinical Trials listed on BioPortfolio]

Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

This is a two center, open label, non-randomized Phase II study of lenvatinib in adult subjects with recurrent or refractory advanced cancers with aberration(s) in FGF/FGFR signaling. Trea...

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

This is a phase I study, which tests the safety of different doses of lenvatinib in combination with cetuximab, to see which dose is the safest in people. This study will help find out if ...

Lenvatinib and Pembrolizumab Simultaneous Combination Study

The efficacy and safety of the use of pembrolizumab in combination with lenvatinib.

Lenvatinib in Second Line Endometrial Carcinoma

The primary objective of this multicenter, randomized phase II trial is to assess the efficacy, as measured by progression-free survival (PFS), of lenvatinib compared to doxorubicin in adv...

Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma

The purpose of this study is to find out what effects, good and/or bad, the drug lenvatinib has on the patient and on adenoid cystic carcinoma. This type of cancer study is called a phase ...

PubMed Articles [38 Associated PubMed Articles listed on BioPortfolio]

Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer.

Once-daily lenvatinib 24 mg is the approved dose for radioiodine-refractory differentiated thyroid cancer. In a phase 3 trial with lenvatinib, the starting dose of 24 mg was associated with a relati...

Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma.

Glioblastoma is the most common and devastating type of malignant brain tumor. We recently found that eribulin suppresses glioma growth in vitro and in vivo and that eribulin is efficiently transferre...

Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report.

Eribulin, a non-taxane inhibitor of microtubule dynamics, is approved for the treatment of metastatic breast cancer patients after progression with anthracyclines and taxanes. Nevertheless, to our kno...

Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.

Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy in children and adolescents. Infrequently, children with PTC may present with or develop disease not amenable to surgery or radi...

Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.

Predictive factors of response to eribulin are lacking. We aimed to investigate the activity and safety of eribulin in a real-world population of metastatic breast cancer (MBC) patients and to identif...

Medical and Biotech [MESH] Definitions

None available.

More From BioPortfolio on "Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma"

Quick Search


Searches Linking to this Trial